SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Targacept (TRGT) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (6)9/29/2006 11:36:41 AM
From: keokalani'nuiRead Replies (1) | Respond to of 40
 
Athenagen has an oral nicotinic acetylcholine alpha-7 receptor agonist in P2 for cognitive enhancement in schizophrenics with data expected by EOY, P2 in AD may start before EOY.

Memy also has a similar program that looks just so-so, so far.

I'm sure there is a lot more competition.



To: keokalani'nui who wrote (6)10/2/2006 8:35:31 PM
From: kenhottRead Replies (1) | Respond to of 40
 
I don't remember any of this detail. Why? I took my look at them in 05 not 06 when they actually IPOd. Pretty funny..... ya.

I will say that I was not very impressed with J. Donald deBethizy (him with the funny name) back then. I see he is still the head. I don't remember the other people but I was not too impress with them either except for one.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News